{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:38:19Z","timestamp":1785209899959,"version":"3.55.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to analyze the clinical features of anti-PM\/Scl antibodies in Chinese patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We reviewed the clinical data of anti-PM\/Scl antibody-positive patients, including their long-term follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 30 patients carried anti-PM\/Scl antibodies, 21 (70%) were females, and the mean age was 55.4 years, 15 (50%) and 10 (33.3%) patients were positive for anti-PM\/Scl-75 and anti-PM\/Scl-100, respectively. Fifteen cases (50%) were diagnosed as inflammatory myopathy, namely, 11 dermatomyositis (DM) and 4 polymyositis (PM). Five (16.7%) patients were diagnosed with overlap syndrome, and only one (3.3%) was diagnosed as systemic sclerosis. The other 9 (30%) patients were classified as undifferentiated connective tissue disease. Twenty-six (86.7%) had interstitial lung disease (ILD) and was the sole manifestation in 8 (26.7%) patients, 15 (58.0%) showed non-specific interstitial pneumonia based on high-resolution CT or lung biopsy. The majority of patients (95%) with mild and moderate groups on basis of pulmonary function tests. Compared to the anti-PM\/Scl-100 group, the occurrence of clinical characteristics was not significantly different from the anti-PM\/Scl-75 group, except the levels of C-reactive protein and erythrocyte sedimentation rate in the anti-PM\/Scl-75 antibody-positive group were higher (<jats:italic>p<\/jats:italic> &amp;lt; 0.05). All patients with positive Ro-52 antibodies had ILD and were more likely to develop skin rash in the group with Ro-52 (<jats:italic>p<\/jats:italic> = 0.024). With a follow-up of the present cohort, 70.8% improved with treatment, but 16.7% of patients are easy to relapse.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The anti-PM\/Scl antibody occurred frequently in DM\/PM patients, ILD was the major clinical feature, especially in patients combined with Ro-52. Some patients may complicate with ILD alone without extrapulmonary manifestations. Anti-PM\/Scl antibodies positive patients were responsive to treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2021.778211","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T05:12:25Z","timestamp":1642482745000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Interstitial Lung Disease Is a Major Characteristic of Patients Who Test Positive for Anti-PM\/Scl Antibody"],"prefix":"10.3389","volume":"8","author":[{"given":"Yongpeng","family":"Ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linrong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1172\/JCI108616","article-title":"Antinuclear antibody with distinct specificity for polymyositis","volume":"59","author":"Wolfe","year":"1977","journal-title":"J Clin Invest."},{"key":"B2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/BF00915286","article-title":"Antibodies to a nuclear\/nucleolar antigen in patients with polymyositis overlap syndromes","volume":"4","author":"Reichlin","year":"1984","journal-title":"J Clin Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1084\/jem.173.4.941","article-title":"Molecular characterization of an autoantigen of PM-Scl in the polymyositis\/scleroderma overlap syndrome: a unique and complete human cDNA encoding an apparent 75-kD acidic protein of the nucleolar complex","volume":"173","author":"Alderuccio","year":"1991","journal-title":"J Exp Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1084\/jem.176.4.973","article-title":"Cloning and characterization of the cDNA coding for a polymyositis-scleroderma overlap syndromerelated nucleolar 100-kD protein","volume":"176","author":"Bl\u00fcthner","year":"1992","journal-title":"J Exp Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.autrev.2007.01.013","article-title":"Novel aspects of autoantibodies to the PM\/Scl complex: clinical, genetic and diagnostic insights","volume":"6","author":"Mahler","year":"2007","journal-title":"Autoimmun Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e2068","DOI":"10.1212\/WNL.0000000000005638","article-title":"Muscular and extramuscular clinical features of patients with anti-PM\/Scl autoantibodies","volume":"90","author":"De Lorenzo","year":"2018","journal-title":"Neurology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.resinv.2019.12.003","article-title":"Clinical, radiological, and pathological features of anti-asparaginyl tRNA synthetase antibody-related interstitial lung disease","volume":"58","author":"Naoto","year":"2020","journal-title":"Respir Investig."},{"key":"B9","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1164\/ajrccm.161.2.ats3-00","article-title":"Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.2169\/internalmedicine.2402-18","article-title":"An anti-PM\/Scl-75 antibody-positive Japanese woman who developed inflammatory myopathy","volume":"58","author":"Nakamura","year":"2019","journal-title":"Intern Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/art.20056","article-title":"PM-Scl-75 is the main autoantigen in patients with the polymyositis\/scleroderma overlap syndrome","volume":"50","author":"Raijmakers","year":"2004","journal-title":"Arthritis Rheum."},{"key":"B12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13075-015-0573-x","article-title":"Anti-PM\/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma","volume":"17","author":"Muro","year":"2015","journal-title":"Arthritis Res Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/art.22237","article-title":"Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy","volume":"55","author":"Selva-O'Callaghan","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B14","first-page":"129","article-title":"Anti-pm\/scl antibodies in connective tissue disease: clinical and biological assessment of 14 patients","volume":"24","author":"Vandergheynst","year":"2006","journal-title":"Clin Exp Rheumatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1111\/1756-185X.13019","article-title":"Anti-PM\/Scl antibody-positive dermatomyositis in a Japanese patient: a case report and review of the literature","volume":"20","author":"Kohara","year":"2017","journal-title":"Int J Rheum Dis."},{"key":"B16","first-page":"S12","article-title":"Anti-PM-Scl antibody in patients with systemic sclerosis","volume":"30","author":"Koschik","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1365-2133.2009.09484.x","article-title":"Long-term outcome of patients with polymyositis\/dermatomyositis and anti-PM-Scl antibody","volume":"162","author":"Marie","year":"2010","journal-title":"Br J Dermatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/rheumatology\/kew382","article-title":"Resolution of paraneoplastic PM\/Scl-positive systemic sclerosis after curative resection of a pancreatic tumour","volume":"56","author":"Bruni","year":"2017","journal-title":"Rheumatology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"keab152","DOI":"10.1093\/rheumatology\/keab152","article-title":"The clinical phenotype of systemic sclerosis patients with anti-PM\/Scl antibodies: results from the EUSTAR cohort","volume":"12","author":"Lazzaroni","year":"2021","journal-title":"Rheumatology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"102355","DOI":"10.1016\/j.autrev.2019.102355","article-title":"Interstitial lung disease associated with anti-PM-Scl antibody: a single center experience","volume":"18","author":"Ussavarungsi","year":"2019","journal-title":"Autoimmun Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3899\/jrheum.090652","article-title":"Interstitial lung disease associated with anti-PM\/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?","volume":"37","author":"Lega","year":"2010","journal-title":"J Rheumatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"R22","DOI":"10.1186\/ar2614","article-title":"Antibodies against PM\/Scl-75 and PM\/Scl-100 are independent markers for different subsets of systemic sclerosis patients","volume":"11","author":"Hanke","year":"2009","journal-title":"Arthritis Res Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.3390\/jcm8112013","article-title":"Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course","volume":"8","author":"Cavagna","year":"2019","journal-title":"J Clin Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12931-014-0154-6","article-title":"Predictors of diagnosis and survival in idiopathic pulmonary fibrosis and connective tissue disease-related usual interstitial pneumonia","volume":"15","author":"Moua","year":"2014","journal-title":"Respir Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s11739-011-0517-7","article-title":"The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases","volume":"6","author":"Murdaca","year":"2011","journal-title":"Intern Emerg Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"046013","DOI":"10.1088\/1752-7155\/10\/4\/046013","article-title":"Th-17 cytokines and interstitial lung involvement in systemic sclerosis","volume":"10","author":"Rolla","year":"2016","journal-title":"J Breath Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.2174\/1381612827666210903103935","article-title":"Covid-19 and rheumatic autoimmune systemic diseases: role of pre-existing lung involvement and ongoing treatments","volume":"27","author":"Ferri","year":"2021","journal-title":"Curr Pharm Des."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.778211\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T05:12:30Z","timestamp":1642482750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.778211\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":27,"alternative-id":["10.3389\/fmed.2021.778211"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.778211","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]},"article-number":"778211"}}